Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > October 22, 2025
Daily News
October 22, 2025
- MFN Drug Pricing Already Affecting 4 Firms’ R&D Plans in Japan, EFPIA Chief Flags Fallout
October 22, 2025
- Astellas JV Aims to Bridge “Valley of Death” in Cell Therapy Manufacturing: CEO
October 22, 2025
- JPMA Chief Hails Takaichi’s Election as PM, Calls for Stronger Innovation Ecosystem
October 22, 2025
- Krystal Launches Japan’s First DEB Therapy Vyjuvek Gel
October 22, 2025
- Japanese Drug Makers’ Domestic Sales Inch Up on Shift toward Specialty Areas: Fuji Keizai
October 22, 2025
- Takaichi Faces Tough Balancing Act on Healthcare, Nursing Reform
October 22, 2025
- LDP’s Takaichi Elected as Japan’s First Female Prime Minister
October 22, 2025
- Sawai, Asahi Kasei Reach Settlement in Teribone Patent Suit
October 22, 2025
- Sumitomo Pharma Drops Option on FunPep’s FPP003 Peptide
October 22, 2025
- Daiichi Sankyo’s Anti-CDH6 ADC Hits Primary Goal in Global PII
October 22, 2025
- Daiichi Sankyo Unveils Dose-Escalation Data on TA-MUC1-Targeting ADC
October 22, 2025
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…